FDA Approves Lilly's Alzheimer's Disease Drug; Donanemab now with the brand name of Kisunla slows cognitive and functional decline by up to 35% and has a list price of $695.65 per vial.

Press/Media

Period1 Jul 2024

Media coverage

1

Media coverage

  • TitleFDA Approves Lilly's Alzheimer's Disease Drug; Donanemab now with the brand name of Kisunla slows cognitive and functional decline by up to 35% and has a list price of $695.65 per vial.
    Media name/outletManaged Healthcare Executive (MJH)
    Country/TerritoryUnited States
    Date1/07/24
    PersonsHoward Fillit
View all 1
View less